In a patient with significant tongue movements and lip‑smacking (orofacial dyskinesia), is Austedo (dextromethorphan/quinidine) appropriate?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Austedo is NOT appropriate for this patient

You are describing tardive dyskinesia (TD), and Austedo (deutetrabenazine) is actually FDA-approved to TREAT this condition, not cause it. The significant tongue movements and lip-smacking you're observing are classic orofacial manifestations of TD—an involuntary movement disorder typically caused by long-term dopamine antagonist exposure 1.

Critical Clarification: What is Austedo?

Austedo (deutetrabenazine) is a VMAT2 inhibitor specifically FDA-approved for treating:

  • Tardive dyskinesia (movements in face, tongue, or other body parts that cannot be controlled)
  • Chorea associated with Huntington's disease

2

This is fundamentally different from dextromethorphan/quinidine, which you may be confusing it with. Let me address both:

If You're Asking About Austedo (Deutetrabenazine):

YES—Austedo IS appropriate for treating TD with orofacial dyskinesia

Austedo is specifically indicated for exactly what you're describing: involuntary tongue movements and lip-smacking characteristic of tardive dyskinesia 2.

Key Treatment Considerations:

  • Dosing: Start low and titrate weekly based on response and tolerability. Maximum dose is 48 mg/day (or 36 mg/day if on strong CYP2D6 inhibitors) 2

  • Monitoring requirements:

    • Baseline AIMS (Abnormal Involuntary Movement Scale) assessment 3, 4
    • Screen for depression/suicidality (black box warning in Huntington's patients, though less relevant in TD) 2
    • Baseline ECG if cardiac risk factors (QTc prolongation risk) 1, 2
  • Common adverse effects: Somnolence, sedation, parkinsonism, akathisia 2

  • Contraindications:

    • Active liver disease
    • Concurrent use with reserpine, MAOIs, tetrabenazine, or valbenazine
    • Patients with suicidal ideation (in Huntington's disease context) 2

If You're Asking About Dextromethorphan/Quinidine (Nuedexta):

NO—Dextromethorphan/quinidine is NOT appropriate for TD

Dextromethorphan/quinidine is FDA-approved only for pseudobulbar affect (pathological laughing/crying), NOT for tardive dyskinesia 5, 6, 7.

The 2019 AGS Beers Criteria specifically advises CAUTION with dextromethorphan/quinidine in dementia patients due to limited efficacy for behavioral symptoms while increasing fall risk and drug interactions 8. It should NOT be used for TD.

While one small pilot study explored dextromethorphan/quinidine for levodopa-induced dyskinesia in Parkinson's disease 9, this is:

  • A completely different condition than TD
  • Based on preliminary evidence only
  • Not FDA-approved for this indication

First-Line Management Algorithm for TD:

  1. Confirm the diagnosis: Use AIMS to document baseline severity 3, 4

  2. Identify the causative agent: Review all current and past dopamine antagonists (typical antipsychotics > atypical antipsychotics) 3, 1, 3

  3. Risk-benefit assessment:

    • If patient is psychiatrically stable: Attempt to reduce dose or switch to lower-risk atypical antipsychotic 3
    • If patient requires continued antipsychotic: Maintain current regimen and add VMAT2 inhibitor 3
  4. Initiate VMAT2 inhibitor (Austedo or valbenazine):

    • These are the only FDA-approved treatments for persistent TD 4
    • Start Austedo at 6 mg twice daily, titrate weekly by 6 mg/day increments 2
    • Monitor with AIMS every 4-6 weeks during titration 4
  5. Avoid common pitfalls:

    • Do NOT use anticholinergics (ineffective for TD and may worsen symptoms) 3
    • Do NOT abruptly stop antipsychotics (may cause withdrawal dyskinesia) 3
    • Monitor for parkinsonism/akathisia as VMAT2 inhibitors can cause these 2

Critical Safety Considerations:

QTc prolongation risk: Both quinidine (in dextromethorphan/quinidine) and Austedo can prolong QTc 1, 8, 2. Obtain baseline ECG if:

  • Age >65 years
  • Cardiac history
  • Concurrent QT-prolonging medications
  • Electrolyte abnormalities

Drug interactions: Austedo requires dose reduction (max 36 mg/day) with strong CYP2D6 inhibitors like paroxetine, fluoxetine, quinidine, or bupropion 2

Sedation: Warn patients about driving/operating machinery until stable on medication; avoid alcohol and other CNS depressants 2

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.